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Abstract
Angiotensin II acts through two pharmacologically distinct receptors known as AT1 and AT2. Duplication of the AT1
receptor in rodents into At1a and b subtypes allows tissue-speciﬁc expression of the AT1b in adrenal and pituitary tissue.
Adrenal expression of this receptor is increased in the offspring of rat mothers exposed to a low-protein diet and this is
associated with the undermethylation of its promoter. This phenomenon is blocked by the inhibition of maternal
glucocorticoid synthesisby metyrapone. We have mappedthe transcriptional start site of the promoter and demonstrated
that a 1.2 kbp fragment upsteam of this site is effective in driving luciferase expression in mouse Y1 cells. A combination
of bioinformatic analysis, electrophoretic mobility shift analysis (EMSA), and mutagenesis studies demonstrates: i) the
presence of a putative TATA box and CAAT box; ii) the presence of three Sp1 response elements, capable of binding
SP1; mutation of any pair of these sites effectively disables this promoter; iii) the presence offour potential glucocorticoid
response elementswhich each bind glucocorticoid receptor in EMSA, although only two confer dexamethasone inhibition
on the promoter; iv) the presence of two AP1 sites. Mutagenesis of the distal AP1 site greatly diminishes promoter
function but this is also associated with the loss of dexamethasone inhibition. These studies will facilitate an
understanding of the mechanisms by which fetal programming leads to long term alterations in gene expression and the
development of adult disease.
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Introduction
The renin–angiotensin system plays a major part in
the regulation of salt and water metabolism and
consequently of blood pressure in mammals. Key
components of this system are the receptors for
angiotensin. Two G protein-coupled receptors (the
AT1 and AT2 receptors) have been identiﬁed in
mammals which have distinctive pharmacological and
signal transducing characteristics (Clauser et al. 1996,
Inagami 1999). However, the majority of the short-term
salt and water regulatory functions are mediated
through the AT1 receptor. In rodents, a duplication
of the AT1 receptor gene has formed the AT1a and b
receptor subtypes (encoded by Agtr1a and Agtr1b
respectively). Although the ligand binding and signal
transducing features of these two highly homologous
receptors are indistinguishable, they do differ in their
sites of expression, with the AT1b largely restricted to
the adrenal cortex and pituitary (Kakar et al. 1992,
Sandberg et al. 1992).
The physiological importance of the AT1b is not
immediately obvious when studied in the mouse
knockout models as compensatory increases in Agtr1a
expression and/or the function can obscure its role.
Agtr1b-knockout animals have impaired thirst-sensing
and drinking, but are not hypotensive. However, in
Agtr1a-knockout animals, studies with an AT1 antagon-
ist further reduced the blood pressure, and an
angiotensin II pressor effect mediated by the AT1b
was observed. These aspects are reviewed by Audoly
et al. (2000).
The selective advantage of having functionally the
same receptor derived from distinct genes at these sites
is not clear, but one probable beneﬁt is the opportunity
for each subtype to be driven and regulated by different
promoters. The more widely active Agtr1a promoter
has been characterized in some detail (Murasawa et al.
1993, 1995, Takeuchi et al. 1993, Bhat et al. 1994).
However, little work has been reported on the rat Agtr1b
promoter following its initial characterization (Guo &
Inagami 1994).
The Agtr1b is of interest to us in view of our previously
reported ﬁnding that a maternal low-protein diet
results in an increased expression of the adrenal
Agtr1b by 1 week of age in offspring (Bogdarina et al.
2007). It has previously been shown in this model of
fetal programming that the adrenal shows increased
mineralocorticoid responsiveness to Ang II (McMullen
et al. 2004, McMullen & Langley-Evans 2005) and this
increased expression of Agtr1b provides a potential
mechanism for the hypertensive phenotype that
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(Langley-Evans 1997, 2000, Bertram & Hanson 2002).
We showed that the putative Agtr1b promoter was
undermethylated in this model, which may account
for the increased gene expression (Bogdarina et al.
2007).NosigniﬁcantchangesintheexpressionofAgtr1a
or any other component of the renin–angiotensin
system were found in any tissue studied at this early age.
Several theories for the development of fetal
programming have been proposed (e.g. Simmons
2005, Fernandez-Twinn & Ozanne 2006, Le ´vy-Marchal
& Czernichow 2006, Gluckman & Hanson 2007). One
of the most widely accepted hypotheses is that
maternal stress resulting from various causes leads to
increased fetal exposure to maternal glucocorticoids
and hence long-term alteration in gene expression or
cell number in offspring (Langley-Evans 1997, Bertram
& Hanson 2002). Since we have found that fetal
programming leads to altered Agtr1b promoter
methylation, we were particularly interested to inves-
tigate the possibility that glucocorticoids might alter
DNA methylation of this gene. Administration of
metyrapone, an inhibitor of corticosterone pro-
duction, during the ﬁrst 2 weeks of pregnancy in rats
eating a low-protein diet is able to reverse the
overexpression and to normalize the undermethyla-
tion of the Agtr1b gene (manuscript submitted). We
have therefore set out to characterize this promoter in
greater detail and in particular to investigate the
mechanisms of any interaction with glucocorticoids
which might in turn lead to alterations in methylation
of this gene during development.
Methods
Cell culture, transfections, and luciferase assay
Mouse adrenocortical Y1 cells were maintained in high
glucose DMEM/F10 medium (1:1) supplemented with
2.5% fetal bovine serum (FBS), 12% horse serum
(HS), and penicillin/streptomycin at 37 8C and in 5%
CO2. For transfection, 200 ng of each plasmid were
co-transfected with 20 ng of the pRL-CMV Renilla
control vector (Promega, Southampton, UK) into cells
in 12-well plates using calcium phosphate precipi-
tation. Thirty-six hours later the cells were washed with
PBS, lysed and the promoter activity was measured
using the Dual Luciferase reporter assay protocol
(Promega) with results normalized to Renilla luciferase
activity. All experiments were performed three times,
each time in triplicate. For dexamethasone stimu-
lation experiments the cells were washed in PBS and
cultured in fresh DMEM/F10 supplemented with
dextran-coated charcoal-treated FBS and HS. Cells
were stimulated with 10
K7 M dexamethasone for 6 h.
DNA manipulations
50-Rapid ampliﬁcation of cDNA ends (RACE) was
performed using GeneRacer kit (Invitrogen) according
to the manufacturers instructions. Gel puriﬁed PCR
products were cloned into the TOPO vector (Invi-
trogen) and sequenced.
Using rat adrenal genomic DNA as a template for
PCR with primers (F-AGAGCTCCTTTCCATCTGTTT-
GTTTCTG/R_ GATAGATCTTCCCAAGGTGGCAAG),
a1 .3 kbp PCR product, containing the 50-region of the
Agtr1b promoter was cloned into SacI-BglII sites of
pGL3-basic vector. This was subsequently digested with
SacI and BamHI, the 1178 bp fragment was gel puriﬁed
and recloned into SacI-BglII sites of pGL3. This
plasmid, pGL3AT1b was used in further experiments
for site-directed mutagenesis of three CpG sites.
pGL3AT1b was used as a PCR template to create serial
50 deletions of the promoter containing a 202 bp
fragment or a 85 bp fragment of the Agtr1b promoter.
Both fragments were cloned into SacI and BglII
digested pGL3 basic vector. Mutated CpG sites in the
proximal Agtr1b promoter were generated using the
QuikChange XL site-directed mutagenesis protocol
(Stratagene, Cedar Creek, TX, USA). Mutations were
conﬁrmed by sequencing. For oligonucleotide
sequences for PCR and mutagenesis, see the Supple-
mentary Table 1 in the online version of the Journal of
Molecular Endocrinology at http://jme.endocrinology-
journals.org/content/vol43/issue2/.
Electrophoretic mobility shift assays
Preparation of nuclear extracts – 10
6 HeLa cells grown
in DMEM with 10% FBS were lysed with Dignam buffer
A (10 mM HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl,
0.5 mM dithiothreitol (DTT)) using 0.1% NP-40. After
isolation of nuclei by centrifugation, the proteins were
extracted at 4 8C for 60 min with Dignam buffer C
(20 mM HEPES, pH 7.9, 25% glycerol, 0.42 M NaCl,
1.5 mM MgCl2,0 .2 mM EDTA, 0.5 mM DTT) in the
presence of protease inhibitors (0.5 mM phenylmethyl-
sulfonylﬂuorid, 1 mM benzamidine, 30 mg/ml leupep-
tin, 5 mg/ml aprotinin, 5 mg/ml pepstatin). Nuclear
extract was aliquoted and stored at K80 8C.
Electrophoretic mobility shift assays (EMSAs) were
performed in a 20 ml binding reaction containing 10 mg
of the nuclear extract. Double-stranded oligonucleo-
tides were labeled using [g-
32P] ATP (Perkin Elmer,
Waltham, MA, USA) and T4 polynucleotide kinase
(New England Biolabs, Hitchin, Hertfordshire, UK)
and puriﬁed from 15% PAGE. The reaction mixtures
were incubated on ice for 10 min, then
32P-labeled
probe was added and the incubation was continued for
another 30 min at RT. In supershift experiments, the
nuclear extract was preincubated on ice with anti-Sp1
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32P-labeled
probe. DNA–protein complexes were separated on
4–5% non-denaturing polyacrylamide gel in 0.5!TBE
for 3 h at 200 V at 4 8C and subjected to autoradiog-
raphy after drying. For competition experiments,
100-fold molar excess of unlabeled competitor was
pre-incubated with the nuclear extract for 15 min
before labeled probe was added.
Antibodies used for supershift studies were anti-c-fos
(K-25): sc-253, and anti-c-jun: sc-44 from Santa Cruz
(Wembley, Middlesex, UK), anti-GR (PA1-510A) rabbit
polyclonal antibody from Afﬁnity BioReagents
(Cambridge, UK) and anti-SP1 rabbit polyclonal
antibody (2873-24) – a gift from Prof Steve Jackson,
Gurdon Institute, Cambridge, UK.
Results
Promoter mapping
The start site of transcription of the rat Agtr1b gene was
identiﬁed using the 50 RACE technique (Fig. 1a).
Sequencing of cloned extended products suggested
the existence of several potentialtranscription start sites
although the major site was located at position 1437
(Gene Bank Accession number U01033) and 11/20
sequenced clones revealed a start site in this position.
Examination of 1.6 kbp of genomic sequence upstream
of this start site showed a sequence containing a
probable TATA box (at K27 bp), a weak CAAT box at
K59 bp and 7 CpG sites, of which three were located in
the proximal promoter region. Analysis in silico using
Transcription Element Search System (TESS, http://
www.cbil.upenn.edu/tess) suggested the presence of
threeputativebindingsitesforSp1(50 endatK43,K81
and K104 bp relative to the transcriptional start site).
CpG sites 1 and 2 are located in one of the Sp1 binding
sites (site 2 – Sp1-2) and CpG site 3 in Sp1-3 (Fig. 1b).
Binding sites for several other transcription factors
includingAP1(positionK98andK135 bp)werenoted.
Promoter function
Toassess the functionof this putative promoter, a1.2k b
fragment was cloned into the pGL3 basic luciferase
reporter vector. When transiently transfected into
mouse Y1 adrenocortical cells signiﬁcant luciferase
activity was recorded. Deletion of this promoter to only
the most proximal 202 bp showed that most promoter
activity was retained in this fragment, although further
deletion to 85 bp which removed both putative AP1
sites and the distal Sp1 site resulted in almost complete
loss of activity (Fig. 2a). The three CpG sites of the
proximal promoter (K77, K72, K42) were individually
or simultaneously mutated changing C for T. Mutation
in CpG1 reduced luciferase activity to about 40% of
wild-type, mutation in CpG2 had little effect, and
mutation in CpG3 reduced the activity to about 5% of
wild-type. Combinations of any two CpG mutations or
all three obliterated promoter activity (Fig. 2b). We had
previously reported that in vitro methylation of these
CpG sites resulted in complete loss of promoter activity
(Bogdarina et al. 2007).
EMSA
All three of the proximal promoter CpG sites lie within
the predicted Sp1 sites Sp1-2 or Sp1-3. Evidence for
the interaction with Sp1 was sought by EMSA using
Figure1 MappingoftheAgtr1bpromoter.(a)Agarosegelshowing
the products of the 50 RACE. Two major products (a and b) are
found using independent reverse gene speciﬁc primers located at
positions 639–654 (GSP1) and 537–559 (GSP2) of the Genebank
genomic sequence S69961. Sequence analysis showed that the
majority of clones derived from the ‘a’ band mapped a start site
equivalent to position 1437 of the Genebank 50 region and exon 1
sequence U01033. GR50 is GeneRacer 50 primer and GRn is
GeneRacer nested primer from Invitrogen. (b) A diagrammatic
representation of 1.3 kbp of promoter indicating the location of
more distal GREs. Three CpGs sites located within the Sp1-2 and
Sp1-3 are shown as closed circles. (c) DNA sequence of the
putative proximal promoter showing the transcriptional start site
(C1), the probable TATA, CAAT box (both underlined), GRE4,
AP1-1 and -2 (gray boxes), and three SP1 sites. Vertical arrows
labeleddel202anddel85representthe50 endsofthetwodeletion
constructs of the promoter studied in luciferase assays.
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sponding to Sp1-1, 2 or 3. All probes bind a complex of
a similar mobility to that which binds a consensus Sp1
site (Fig. 3a – arrowed). A mutated Sp1-2 or Sp1-3
oligonucleotide was unable to bind a complex (Fig. 3a).
One hundred-fold molar excess of the consensus Sp1
sequence effectively competes for complex binding on
both these Sp1 probes (Fig. 3b). The mutant consensus
sequence or mutant Sp1-2 or Sp1-3 sequence was
unable to compete (Fig. 3b). Similar results are found
using Y1 cell nuclear extracts (data not shown). Further
evidence that this factor was Sp1 was sought using
supershift with Sp1 antibodies. As can be seen in Fig. 3c,
complexes formed with both probes and the consensus
Sp1 probe show supershift. We had previously shown
that the inﬂuence of each of these CpG sites on the
promoter function was signiﬁcantly reduced when
methylated in vitro (Bogdarina et al. 2007). We therefore
investigated whether Sp1 binding was inﬂuenced by
methylation using speciﬁcally methylated probes in
EMSA. In all cases when each of the CpG sites were
methylated on both strands a complex migrating as
for the unmethylated probe was seen and was super-
shifted by Sp1 antibody. Therefore, alternative
mechanisms such as methyl-DNA binding proteins
binding to these methylated CpG sites are more likely
to explain the inhibition of gene expression associated
with methylation.
Glucocorticoid regulation
Using Y1 cells transfected with the full length Agtr1b -
luciferase vector pGL3AT1b, it was possible to
demonstrate a potent suppressive effect of 6 h
treatment with dexamethasone on luciferase activity.
Dose response studies indicated an IC50 of 4.4
!10
K10 M( Fig. 4a).
To investigate whether the glucocorticoid effect was
likely to be mediated through the putative GREs their
ability to bind glucocorticoid receptor was investigated
by EMSA. This conﬁrmed that all four GREs bound
a complex with similar mobility to that formed with
a consensus GRE, and that a 100-fold excess of a
consensus GRE competed these away. Addition of
dexamethasone (10
K7 M) to the culture medium for
6 h did not inﬂuence the intensity or size of complex
formation (Fig. 4b). However, site-directed mutagen-
esis of GRE1 and 3, but not GRE2 and 4 in the
context of the full length promoter led to loss of
signiﬁcant glucocorticoid responsiveness (Fig. 4c),
Figure 3 Sp1 binding to proximal promoter elements. (a) EMSA
using a consensus Sp1 or Sp1-2 or Sp1-3 as probes. All probes
bind a similar sized complex (arrowed) although mutated Sp1-2 or
Sp1-3 fail to bind. (b) Sp1-2 and Sp1-3 probes are competed by a
consensus Sp1 sequence, but not by mutant sequences. (c) The
consensus Sp1 and Sp1-1, -2, and -3 probes are supershifted by
antibody to Sp1 (arrow labeled ss). DNA methylation of Sp1-2 or
Sp1-3 (labeled SP1-2met and Sp1-3met) does not reduce
complex formation (unlabeled arrow) or supershifted band after
pre-incubation with antibody.
Figure 2 Function of the Agtr1b promoter in Y1 cells. (a) The full
length, del 202, and del 85 promoter fragments were expressed in
mouse Y1 cells and promoter activity monitored using the Dual
Luciferase system. Loss of sequences upstream of Sp1-2 results
in greatlyreducedpromoterfunction. (b)Functionalanalysisof the
full length promoter and derivatives containing mutations of the
Sp1 sites is shown in (a). Mut1 is a mutation in the Sp1-2 site at
positions K77, mut2 is a mutation in the Sp1-2 site at K72, and
mut3 is a mutation in the Sp1-3 site at K42. Mut 123 is a
combination of all three mutations, and mut13, mut23, and mut12
mutations in the pairs of CpG sites so identiﬁed. All mutations
represent a replacement of a C by T.
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in part through these two sites (GRE1 and 3) acting as
a negative GRE.
An alternative mechanism for glucocorticoid inhi-
bition of gene expression is that it may be mediated
through an AP1 site. Two consensus AP1 sites are
present in the proximal promoter, one of which
(AP1-2) overlaps Sp1-1 site, whilst the other (AP1-1)
overlaps GRE4. EMSA demonstrated that the putative
AP1-2 site formed a complex that had similar mobility
to that of a consensus AP1 site. Mutation of this
site prevented formation of this complex which was
also competed by a consensus AP1 oligonucleotide
(Fig. 5a). The AP1-1 site also formed a similar
complex which was competed by a AP1 consensus
oligonucleotide and by GRE4, but not by GRE1, GRE2,
GRE3 or mutant consensus AP1 (Fig. 5b). Supershift
experiments with anti-c-fos,a n t i - c-jun,a n da n t i - G R
suggested AP1 and GR could interact with the AP1-1
sequence (Fig. 5d).
Dexamethasone responsiveness was not affected by
mutagenesis of AP1-1. Mutagenesis of AP1-2 resulted in
greatly reduced activity of the promoter and this was
associated with loss of dexamethasone inhibition
(Fig. 6).
Figure4 Glucocorticoidresponsiveness ofthe proximalpromoter.
(a) The full length promoter-luciferase reporter shows a dose
dependent inhibition by dexamethasone in Y1 cells. (b) EMSA
with a consensus GRE, or GRE1–4 from the Agtr1b shows a
similar complex formation (arrowed) which is not signiﬁcantly
altered by the pre-treatment of cells with dexamethasone. All of
the Agtr1b GRE probes show successful competition by a
consensus GRE. (c) The Agtr1b promoter reporter still shows
adequate function in the presence of mutations of each of the
GREs, and glucocorticoid inhibition is retained with the GRE2 and
GRE4 mutants, but is lost when GRE1 and 3 are mutated. RLU,
relative light units. *P!0.05; **P!0.001.
Figure 5 Characterization of AP1 sites. (a) EMSA demonstrating
that complexes formed on a consensus AP1 sequence and AP1-2
migrate as a complex with similar mobility, and that a consensus
oligonucleotide effectively competes with AP1-2 for binding. Note
that the mutant AP1 sequence also reveals a non-speciﬁc doublet
complex of greater mobility than that formed with AP1. (b) EMSA
demonstrating that complexes formed on AP1-1 and a consensus
AP1 oligonucleotide migrate with similar mobility, but that AP1-1
binding is competed by a consensus oligonucleotide or by the
GRE4 oligonucleotide, but not by a mutant consensus AP1
fragment or the other GRE oligonucleotides. (c) The GRE4 probe
binds a complex that is supershifted by glucocorticoid receptor
antibody (arrow labeled ss), similar to that observed with the
consensusGRprobe.(d) TheAP1-1probebinds a complex thatis
supershifted with anti-c-jun and anti-GR antibodies, and to a
lesser extent with anti-c-fos antibody.
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As outlined in the Introduction, our interest in the
Agtr1b promoter is driven by our observations on
its expression in fetal programming models of
hypertension. One candidate mechanism for this
phenomenon is that stress-induced maternal glucocor-
ticoid excess may provide a common pathway linking
various maneuvers that ultimately lead to similar
cardiovascular and metabolic endpoints in the adult.
Consequently, we were particularly interested to
observe the effects, if any, of glucocorticoids on
expression of the Agtr1b gene. Previously, Chansel
et al. (1996) reported that dexamethasone reduced
Agtr1b mRNA expression in rat mesangial cells, but no
effect of dexamethasone was observed in vascular
smooth muscle cells (Guo et al. 1995). We hypothesized
that glucocorticoid targeting of the Agtr1b gene may
also direct reduced methylation of the gene, and if so, it
would be of great interest to identify the mechanism of
this effect.
In order to achieve this it was necessary to
characterize this promoter and its function in the
adrenocortical cells. Previous studies (Guo & Inagami
1994) had identiﬁed a putative promoter region and
suggested that it may contain glucocorticoid response
elements, though these were not found to be functional
in vascular smooth muscle cells, which do not express
this receptor endogenously. In this work we have
characterized the 50 end of the gene using the RACE
technique and used this information to re-deﬁne the
promoter as a probable TATA-box, CAAT-box, and Sp1
containing promoter. We have shown that Sp1 binds to
three consensus Sp1 sites and this is required for a
normal expression of the gene. Mutation of CpG sites 1
and 3 signiﬁcantly reduces gene expression whereas
mutation of CpG site 2 has little effect. However,
methylation of these CpG sites does not reduce Sp1
binding, as is the case for most, but not all, Sp1 binding
sites (Zhu et al. 2003, Liedtke et al. 2005).
The 1.2 kbp of promoter studied is clearly capable of
signaling a negative glucocorticoid effect in Y1 cells with
an IC50 characteristic of a glucocorticoid receptor
mediated effect. By sequence comparison there are
four potential consensus GREs in this promoter, two of
which correspond to those identiﬁed previously (Guo
et al. 1995). Two of these, GRE1 and 3 appear to
mediate in part the negative glucocorticoid effect.
However, signiﬁcant glucocorticoid inhibition was also
seen with the proximal 202 bp of promoter which only
includes GRE4. This GRE does not seem to inﬂuence
luciferase expression directly, but closely overlies one of
the two AP1 sites in this region. As there are several
examples of negative glucocorticoid effects being
mediated via protein–protein interaction between GR
and AP1 (Yang-Yen et al. 1990, Heck et al. 1994,
Wargnier et al. 1998, Tuckermann et al. 1999) this
alternative was investigated. Mutagenesis of AP1-1 had a
relatively small effect on gene expression and the
glucocorticoid repression was retained. Mutagenesis of
AP1-2 led to substantial loss of expression of the gene,
which was accompanied by loss of glucocorticoid
inhibition raising the possibility that this is an
additional means of glucocorticoid inhibition.
Although the acute negative glucocorticoid
regulation observed in these promoter studies might
appear to contradict the long-term enhancement of
function observed in programmed animals, we believe
the latter effect is mediated by reduced methylation.
Conceivably the interaction of this promoter with the
GR may inﬂuence the deposition of methylated sites
during the critical period of development at which
this occurs.
A further observation of interest is that the Sp1-3
sequence inaddition to consensus sites for GAGA factor
and zeste in exon 1 form a potential polycomb response
element (PRE). PREs are of particular importance in
early development where, in mammalian cells, they may
Figure 6 Role of AP1 sites in dexamethasone responsiveness.
Dexamethasone (10
K6 M) inhibited the activity of constructs
containing the full length promoter and the del 202 construct with
and without a mutated AP1-1 site. Mutation of the AP1-2 site
resulted in greatly reduced promoter activity and no evidence of
additional dexamethasone suppression of this construct was
observed. Statistical comparison was made using Two-way
Anova with a Bonnferroni correction. **P!0.001; ***P!0.0001;
NS, not signiﬁcant (PO0.05).
Figure 7 A diagrammatic representation of the key elements of
the rat Agtr1b promoter (not drawn to scale). The interaction
between GR and the proximal AP1 site (AP1-2) is speculative.
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structure in the surrounding vicinity as a result of
histone methylation (Simon & Tamkun 2002, Lomberk
& Urrutia 2005, Schwartz & Pirrotta 2007, Vasanthi &
Mishra 2008). Susceptibility of a DNA region to
methylation in the course of development may depend
on the chromatin structure and thus be inﬂuenced by
PRE activity. To what extent maternal glucocorticoids
can inﬂuence PRE occupancy is not known.
In summary, we report the characterization of the
Agtr1b promoter in Y1 cells, and glucocorticoid
inhibition of expression has been identiﬁed acting
in part through upstream promoter GREs as well as
other incompletely clear mechanisms. Our ﬁndings
are summarized in Figure 7. How this relates to the
function of this promoter in the perinatal rat adrenal
and its pattern of developmental methylation is not
clear.
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